BridgeBio Pharma Inc

NASDAQ:BBIO   11:34:51 AM EDT
8.99
-0.25 (-2.71%)
Products, Regulatory

Bridgebio Pharma Affiliate Venthera Presents Preliminary Results From Trial Of Vt30 For Venous, Lymphatic, And Venolymphatic Malformations

Published: 06/10/2022 11:46 GMT
BridgeBio Pharma Inc (BBIO) - Bridgebio Pharma Affiliate Venthera Presents Preliminary Results From Clinical Trial of Vt30 (bbp-681) for Venous, Lymphatic, and Venolymphatic Malformations.
Bridgebio Pharma Inc - Across 15 Subjects Treated in Escalating-dose Cohorts, Vt30 Topical Gel Has Been Generally Well-tolerated.
Bridgebio Pharma Inc - No Circulating Drug Was Detected in Plasma With Any of Gel Strengths Studied.
Bridgebio Pharma Inc - Based on Findings Shared During Issva 2022, Venthera Has Tentatively Selected 0.6% Gel for Further Study.
Bridgebio Pharma Inc - Venthera is Currently Seeking Partners to Support Development of Vt30 Topical Gel in Phase 2.